Non-viral delivery for cell & gene therapy
Complex Cargo.
Durable Engineering.
Better Cells.
NaVette’s modular LNP platform is designed specifically for editing primary immune cells, combining complex genetic engineering with the cell fitness needed for next-generation therapies.
How it works
Everything the cell needs, delivered at once.
Complex gene engineering requires multiple components working together. For example, CRISPR-HDR requires an editor, a guide, and a template. NaVette’s modLNP platform can deliver all three in a single particle.
Modular LNP Co-Delivery
Complete editing toolkit in one particle
01 — LOAD
Three cargoes, one particle.
A DNA template, a guide RNA, and an editor mRNA are packaged together inside a lipid nanoparticle. Conventional LNPs carry RNA alone. This one carries the whole toolkit.
DNA template, guide RNA, and editor mRNA, packaged together. Conventional LNPs carry RNA alone.
02 — DELIVER
The particle finds the cell.
A targeting ligand on the surface directs the particle to the cell, where it fuses with the membrane and releases its cargo. No viral vector. No electroporation. Nothing that damages the cell to get inside it.
A targeting ligand directs it to the membrane. No virus, no electroporation.
03 — PULSE
The editor works, then clears.
The guide RNA directs the editor to the target site. The editor makes the cut — then both degrade, leaving no lasting editing machinery in the cell.
The guide directs the editor to the target site. It makes the cut — then both degrade.
04 — PERSIST
The edit remains.
The DNA template integrates into the genome. The change is durable. The cell keeps its viability and its proliferative potential, and expands to therapeutic dose.
The DNA template integrates. The change is durable, and the cell stays healthy.
One particle. A transient pulse. A durable edit.
The people behind the platform.
Founded in early 2025, NaVette is led by industry veterans with proven track records and experience in rapid, iterative product design and development.
The platform
Built to go where viral vectors can't
-
Simplified manufacturing
No viral vector production and no specialized hardware, so cell engineering fits existing workflows.
-
Healthier cells
Gentler editing preserves viability and speeds expansion to therapeutic dose.
-
Larger, more complex payloads
Multi-gene circuits and genome-editing systems beyond the limits of viral vectors.
-
Automation-ready
Closed-system workflows with fewer manual steps and less operator variability.
Let's talk.
Reach out to discuss the following:
- Request a demo.
- How our platform can help you.
- Learn about our science.
Message received.
Someone from the NaVette Bio team will be in touch shortly.